

# DISCOVER HOW NAPOCARES™ CAN HELP YOU ACCESS MYTESI®

## At Napo Pharmaceuticals, Inc., we are committed to helping you access Mytesi® (crofelemer)

That is why we expanded NapoCares, our comprehensive patient support program, to make it easier for eligible patients to receive support to start and continue Mytesi treatment.



### Mytesi is the only FDA-approved treatment for the symptomatic relief of noninfectious diarrhea in adults living with HIV on ART<sup>1</sup>

Mytesi is a non-opioid that works differently from other common diarrhea medicines by balancing the amount of water and salt in the gastrointestinal tract. This helps patients avoid the diarrhea-constipation cycle often caused by other medicines.<sup>1,2,3</sup>

Studies show when taking Mytesi, most patients continue to see relief in their symptoms through week 24 after starting treatment.<sup>2</sup> It's important to continue taking Mytesi consistently to see these improvements, even if the symptom relief seems gradual.



\* Subject to eligibility. Restrictions apply. Rx only. Subject to change or cancellation at any time and without notice.

† Patient must have commercial insurance for eligibility. Subject to change or cancellation at any time and without notice.

Please see Important Safety Information on the following page. Full Prescribing Information for Mytesi is available at [Mytesi.com](http://Mytesi.com).

### NapoCares has support for patients, whether uninsured, underinsured, or insured

We provide a range of services to help you access Mytesi\*:



**Copay Savings Program** to help you save on your out-of-pocket costs<sup>†</sup>



**Patient Assistance Program** for uninsured patients



Support to help you **understand your insurance coverage**



Support for **Prior Authorizations and Appeals**



**Linkage to specialty pharmacies** to fill your prescription



**Mail order pharmacy support**



**Patient call center** to answer any questions

**Mytesi**  
(crofelemer) 125 mg  
delayed-release tablets

#### What is Mytesi?

Mytesi is a prescription medicine that helps relieve symptoms of diarrhea not caused by an infection in adults living with HIV/AIDS on antiretroviral therapy (ART).

# NAPOCARES™ PATIENT SUPPORT PROGRAMS CAN HELP YOU START OR CONTINUE MYTESI

## Mytesi Copay Savings Card\*\*

Most eligible patients will pay no more than \$25 for their Mytesi prescriptions, saving up to \$6,000 per year.

- Patients must re-enroll in the program every 12 months
- The offer is not valid if the patient's prescription plan is fully/partially paid by Medicaid, Medicare, federal, or state government programs

Get your copay savings card by calling 1-888-527-NAPO (6276).



## Patient Assistance Program Benefits\*

Patients may be able to get Mytesi at no cost. Eligible patients may include those who are:



**Uninsured** or have **no insurance coverage** options available



**Unable to afford** the cost of Mytesi



**Below the maximum income** requirements for their household size

## We're Here to Help

To enroll in NapoCares or to learn more about its programs, please call 1-888-527-NAPO (6276) Monday-Friday, 8 am-5 pm CST.

All NapoCares programs are free of charge for Mytesi patients.

### Indications and Usage

Mytesi is indicated for symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy.

### Important Safety Information

Mytesi (crofelemer) is not approved to treat infectious diarrhea (diarrhea caused by bacteria, a virus, or a parasite). Before starting you on Mytesi, your healthcare provider will first be sure that you do not have infectious diarrhea. Otherwise, there is a risk you would not receive the right medicine and your infection could get worse. In clinical studies, the most common side effects that occurred more often than with placebo were upper respiratory tract (sinus, nose, and throat) infection (6%), bronchitis (4%), cough (4%), flatulence (3%), and increased bilirubin (3%).

\* Subject to eligibility. Restrictions apply. Rx only. Subject to change or cancellation at any time and without notice.

† Patient must have commercial insurance for eligibility. Subject to change or cancellation at any time and without notice.

**References:** 1. Mytesi [package insert]. San Francisco, CA: Napo Pharmaceuticals Inc; 2018. 2. MacArthur RD, Clay P, Blick G, Waltzman R, Bell M. Long-term crofelemer provides clinically relevant reductions in HIV-related diarrhea. 9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris, France. Abstract WEPEB0537. 3. MacArthur R, Harkins TN, Brown SJ, et al. Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT Trial): A randomized, double-blind, placebo-controlled, two-stage study. *HIV Clin Trials*. 2013;14(6):261-273.

© Napo Pharmaceuticals, Inc. MYT-C-0002